Novo Nordisk AS (NVO)
102.63
-2.64
(-2.51%)
USD |
NYSE |
Nov 21, 16:00
102.62
-0.01
(-0.01%)
After-Hours: 20:00
Novo Nordisk Enterprise Value: 453.33B for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 453.33B |
| November 20, 2024 | 465.06B |
| November 19, 2024 | 453.33B |
| November 18, 2024 | 440.80B |
| November 15, 2024 | 449.37B |
| November 14, 2024 | 465.32B |
| November 13, 2024 | 472.39B |
| November 12, 2024 | 473.05B |
| November 11, 2024 | 482.08B |
| November 08, 2024 | 473.68B |
| November 07, 2024 | 476.25B |
| November 06, 2024 | 466.15B |
| November 05, 2024 | 487.37B |
| November 04, 2024 | 485.55B |
| November 01, 2024 | 495.46B |
| October 31, 2024 | 495.50B |
| October 30, 2024 | 501.24B |
| October 29, 2024 | 495.64B |
| October 28, 2024 | 497.33B |
| October 25, 2024 | 501.87B |
| October 24, 2024 | 504.32B |
| October 23, 2024 | 512.42B |
| October 22, 2024 | 515.67B |
| October 21, 2024 | 519.50B |
| October 18, 2024 | 522.88B |
| Date | Value |
|---|---|
| October 17, 2024 | 523.46B |
| October 16, 2024 | 522.61B |
| October 15, 2024 | 521.64B |
| October 14, 2024 | 530.40B |
| October 11, 2024 | 531.56B |
| October 10, 2024 | 520.42B |
| October 09, 2024 | 518.06B |
| October 08, 2024 | 518.95B |
| October 07, 2024 | 521.49B |
| October 04, 2024 | 509.69B |
| October 03, 2024 | 509.54B |
| October 02, 2024 | 515.77B |
| October 01, 2024 | 522.58B |
| September 30, 2024 | 527.30B |
| September 27, 2024 | 536.70B |
| September 26, 2024 | 552.48B |
| September 25, 2024 | 564.28B |
| September 24, 2024 | 557.56B |
| September 23, 2024 | 549.81B |
| September 20, 2024 | 566.77B |
| September 19, 2024 | 599.61B |
| September 18, 2024 | 587.05B |
| September 17, 2024 | 586.79B |
| September 16, 2024 | 608.60B |
| September 13, 2024 | 609.04B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
113.82B
Minimum
Mar 20 2020
656.85B
Maximum
Jun 25 2024
299.27B
Average
245.57B
Median
May 24 2022
Enterprise Value Benchmarks
| Ascendis Pharma AS | 7.511B |
| Amgen Inc | 207.22B |
| AstraZeneca PLC | 224.54B |
| Grifols SA | 7.857B |
| Viking Therapeutics Inc | 4.823B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 4.023B |
| Revenue (Quarterly) | 10.51B |
| Total Expenses (Quarterly) | 5.525B |
| EPS Diluted (Quarterly) | 0.9019 |
| Gross Profit Margin (Quarterly) | 84.14% |
| Profit Margin (Quarterly) | 38.28% |
| Earnings Yield | 3.01% |
| Operating Earnings Yield | 3.76% |
| Normalized Earnings Yield | 3.007 |